^
Association details:
| Biomarker: | SF3B1 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Published date:
03/09/2021
Excerpt:
...86 patients with RR-AML who were treated with venetoclax combinations...Azacitidine + venetoclax resulted in higher response rates compared with low-dose cytarabine + venetoclax...Mutations in NPM1 were associated with higher response rates, whereas adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 were associated with worse OS.
DOI:
10.1182/bloodadvances.2020003734
Source:
Title:
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment
Published date:
11/01/2018
Excerpt:
...we observed that AML samples harboring PML-RARA translocations, WT1, and FLT3 with IDH1 mutations are more sensitive to venetoclax, and samples with TET2, KRAS, PTPN11 and SF3B1 mutations are more resistant.
DOI:
https://doi.org/10.1182/blood-2018-175
Source:
Title:
PREFERENTIAL SYNERGISTIC EFFECT OF INDISULAM IN COMBINATION WITH VENETOCLAX AND AZACYTIDINE IN AML CELLS WITH SF3B1 MUTATIONS.
Published date:
05/12/2022
Excerpt:
CONTRADICTING EVIDENCE: In SF3B1-mutated cells, a clear synergistic effect was further observed when indisulam was combined with ABT-199 and azacitidine....Our results indicate that indisulam is preferentially active and synergistic with venetoclax and azacitidine in SF3B1-mutated cells from newly diagnosed, non-treated AML patients.
Secondary therapy:
azacitidine + E7070
